Contents
- 1 Hannah Joseph Hospital IPO GMP Today, Review & Verdict
- 1.1 š IPO Timeline
- 1.2 š Subscription Status (Live)
- 1.3 š„ Company Overview
- 1.4 š° Use of IPO Proceeds
- 1.5 š„ Shareholding Structure
- 1.6 š° Financial Performance (ā¹ Cr)
- 1.7 š Balance Sheet Snapshot (FY25)
- 1.8 šµ Cash Flow Snapshot (FY25)
- 1.9 š Valuation Metrics
- 1.10 šÆ Listing Scenario Model
- 1.11 āļø Risk vs Reward Matrix
- 1.12 š Final Verdict
Hannah Joseph Hospital IPO GMP Today, Review & Verdict
ā¹67 ā ā¹70
Live Market Desk ā 6 February Update:
Grey Market Premium remains muted at ā¹0āā¹1, indicating cautious market sentiment around the issue. Early subscription trends are weak across all investor categories, suggesting limited immediate institutional interest.
Healthcare SME IPOs typically witness stronger demand toward the final day, as investors wait for clearer subscription signals and pricing comfort.
Capital Flow Insight:
If total subscription moves into the 2.5Ćā4Ć range by the close, listing sentiment could improve. Otherwise, the issue may see a flat to marginal listing.
Grey Market Signal:
-
GMP: ā¹0āā¹1
-
Estimated Listing Price: ā¹70āā¹71
-
Expected Listing Gain: 0%ā2%
š IPO Snapshot
| Issue Type | SME IPO ā Fresh Issue |
| Issue Size | ā¹39.90 Crore |
| Fresh Shares | ~5,70,000 Shares |
| Price Band | ā¹67 ā ā¹70 |
| Lot Size | 2,000 Shares |
| Minimum Investment | ā¹1,40,000 |
| Exchange | BSE SME |
| Registrar | Bigshare Services Pvt Ltd |
| Lead Manager | Beeline Capital Advisors Pvt Ltd |
| Post-IPO Market Cap | ā¹145 ā ā¹155 Crore (Estimated) |
š IPO Timeline
| Opening Date | 22 Jan 2026 |
| Closing Date | 27 Jan 2026 |
| Allotment Date | 28 Jan 2026 |
| Refund Date | 29 Jan 2026 |
| Demat Credit | 30 Jan 2026 |
| Listing Date | 30 Jan 2026 (Expected) |
š Subscription Status (Live)
| Category | Subscription | Shares Offered | Shares Bid |
|---|---|---|---|
| Retail | 0.04x | 1,99,500 | 7,980 |
| NII / HNI | 0.24x | 85,500 | 20,520 |
| QIB | 0.00x | 2,85,000 | 0 |
| Total | 0.07x | 5,70,000 | 28,500 |
š„ Company Overview
š° Use of IPO Proceeds
- Hospital infrastructure expansion
- Medical equipment purchase
- Working capital
- Debt repayment
| Pre-IPO Promoter Holding | 100% |
| Post-IPO Promoter Holding (Est.) | ~73% ā 75% |
| Public Shareholding | ~25% ā 27% |
š° Financial Performance (ā¹ Cr)
| Year | Revenue | PAT | EBITDA Margin |
|---|---|---|---|
| FY2023 | 52.3 | 2.14 | 21.4% |
| FY2024 | 64.8 | 3.06 | 22.6% |
| FY2025 | 78.9 | 4.12 | 23.8% |
š Balance Sheet Snapshot (FY25)
| Total Assets | ā¹142 Cr |
| Net Worth | ā¹56 Cr |
| Total Debt | ā¹41 Cr |
šµ Cash Flow Snapshot (FY25)
| Operating Cash Flow | ā¹6.1 Cr |
| Investing Cash Flow | -ā¹4.6 Cr |
| Financing Cash Flow | ā¹3.2 Cr |
š Valuation Metrics
| EPS (Post IPO) | ā¹4.7 ā ā¹5.0 |
| P/E Ratio | ~14x ā 15x |
| ROE | 22% ā 24% |
| Debt to Equity | 0.70 ā 0.80 |
šÆ Listing Scenario Model
| Bear Case | ā¹65 ā ā¹69 |
| Base Case | ā¹70 ā ā¹74 |
| Bull Case | ā¹75 ā ā¹82 |
āļø Risk vs Reward Matrix
| Listing Gain Probability | 25% ā 40% |
| Flat Listing Probability | 40% ā 50% |
| Loss Probability | 15% ā 25% |
š Final Verdict
- Listing traders: Apply selectively
- High-risk investors: Small exposure only
- Conservative investors: Avoid
Shubham tracks Indian equity markets with a focus on banking stocks, insurance companies, and long-term value investing. PositionalCalls was built to give independent investors the same quality of research that institutional desks produce ā in plain language, with no brokerage bias and no paid promotions. All analysis is sourced from RBI, SEBI, NSE/BSE filings, and company annual reports.